Guy Gammon

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

Jörge E. Cortes, Hagop M. Kantarjian, James M. Foran et al. · Journal of Clinical Oncology · 2013 · 358 citations · Full text

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Jörge E. Cortes, Alexander E. Perl, Hartmut Döhner et al. · The Lancet Oncology · 2018 · 259 citations · Full text

Hematological Malignancy, Flt3 Inhibitor, Medicine +7

Induction of Self-Rolerance in T Cells But Not B Cells of Transgenic Mice Expressing Little Self Antigen

Stephen Adelstein, H. Pritchard-Briscoe, Tracy A. Anderson et al. · Science · 1991 · 213 citations

T-regulatory Cell, Immunology, B Cell Tolerance +17

How some T cells escape tolerance induction

Guy Gammon, Eli E. Sercarz · Nature · 1989 · 208 citations

T Cells, T-regulatory Cell, Immunology +8

Prolonged Survival After Complete Resection of Disseminated Melanoma and Active Immunotherapy With a Therapeutic Cancer Vaccine

Eddy C. Hsueh, Richard Essner, Leland J. Foshag et al. · Journal of Clinical Oncology · 2002 · 202 citations